mulation even after the tretinoin/hydroquinone combination had
been stopped (Figure 2). This means the cosmetic formulation
can be used to maintain and continue pigmentation improvement
after prescription therapy has been discontinued for a
comprehensive solution to treat subjects without the negative
consequences of interrupting their treatment regimen (Figure 3).
DISCUSSION
Pigment lightening is an important worldwide appearance
need that is challenging for the dermatologist. The main
prescription pigment treatment is 4% hydroquinone with
no new prescription pigmentation products in the FDA approval
pipeline. Concerns about the safety of hydroquinone
